At a recent meeting in San Antonio, Texas Retina Clinical Research Coordinator Rachel McCullough participated in a panel discussion with study coordinators for EyePoint Pharmaceuticals’ pivotal Phase III LUGANO and LUCIA clinical trials. She shared her insights on overseeing daily clinical trial activities along with managing schedules and the enrollment process.
About the LUGANO and LUCIA Trials
Texas Retina is currently participating in both the LUGANO and LUCIA studies, which are global, randomized, double-masked, aflibercept controlled, non-inferiority Phase III trials assessing the efficacy and safety of Duravyu (formerly EYP-1901) in patients with active wet age-related macular degeneration (AMD), including previously treated and treatment-naïve patients. Duravyu is an investigational sustained delivery maintenance treatment for wet AMD that combines vorolanib, a selective tyrosine kinase (anti-VEGF) inhibitor, with bioerodible Durasert E™. It was designed to potentially reduce the treatment burden for patients with wet AMD.
Each trial is expected to enroll approximately 400 patients globally who will be randomly assigned to a 2.7mg dose of Duravyu or an on-label aflibercept control. Ashkan M. Abbey, MD, serves as Principal Investigator for LUGANO in Texas Retina’s Dallas Main office and in October 2024, dosed the first patient in the trial. Lori E. Coors, MD, is a Principal Investigator for LUGANO in the Plano office. Wayne A. Solley, MD, serves as Principal Investigator for the LUCIA trial in our Arlington office.
For more information about participation in the LUGANO or LUCIA studies, click HERE to contact study coordinators Rachel McCullough (Dallas Main), Tara Keesling (Plano) or Melissa Alva (Arlington).
Physicians can click HERE to directly refer patients for these trials.
To learn more about all the clinical trials currently available at Texas Retina, click HERE.